Recent studies have shown that suppression of XO activity can prevent muscular protein loss by inhibiting the atrogin-1 pathway and may induce resistance against muscular protein loss and atrophy in patients with sarcopenia or cachexia (47, 48). Here, FBXO32 is linked to Cachexia.